상세 보기
ONO-4578 combined with nivolumab (NIVO) and chemotherapy (chemo) as first-line (1L) treatment for patients with HER2-negative unresectable advanced or recurrent (adv/rec) gastric/gastroesophageal junction cancer (G/GEJ): A randomized, double-blind, phase 2 trial (ONO-4578-08).
- Lim, Sung Hee;
- Nakayama, Izuma;
- Ryu, Min-Hee;
- Kim, Jong Gwang;
- Omori, Takeshi;
- ... Sym, Sun Jin;
- 외 13명
Citations
WEB OF SCIENCE
0- 제목
- ONO-4578 combined with nivolumab (NIVO) and chemotherapy (chemo) as first-line (1L) treatment for patients with HER2-negative unresectable advanced or recurrent (adv/rec) gastric/gastroesophageal junction cancer (G/GEJ): A randomized, double-blind, phase 2 trial (ONO-4578-08).
- 저자
- Lim, Sung Hee; Nakayama, Izuma; Ryu, Min-Hee; Kim, Jong Gwang; Omori, Takeshi; Oh, Sang Cheul; Kim, Jin Young; Rha, Sun Young; Lee, Keun-Wook; Machida, Nozomu; Sym, Sun Jin; Narita, Yukiya; Park, Young-Iee; Hara, Hiroki; Hosaka, Hisashi; Kang, Beodeul; Kim, In-Ho; Bai, Li-Yuan; Shitara, Kohei
- 발행일
- 2026-06
- 유형
- Meeting Abstract
- 권
- 44
- 호
- 16_SUPPL